Last reviewed · How we verify
Alginates
Alginates is a Small molecule drug developed by Medical University of South Carolina. It is currently in Phase 2 development. Also known as: Gaviscon Advance.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Alginates |
|---|---|
| Also known as | Gaviscon Advance |
| Sponsor | Medical University of South Carolina |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2, PHASE3)
- Efficacy of a Polyhexanide Biguanide-Based Gel in the Prevention of Biofilm Formation in Pressure Ulcers (EARLY_PHASE1)
- Sorbact TM: Effect of a Microbial Binding Dressing on Wound Healing After Pilonidal Sinus Excision (NA)
- Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS (NA)
- Oral Fosamprenavir + Sodium Alginate for GERD (PHASE2)
- Prevention of Oral Mucositis and Improvement of Quality of Life for Patients With Breast Cancer Undergoing Adjuvant Radiotherapy (PHASE2)
- HONEY for the Treatment of POst-Tonsillectomy Pain (NA)
- Analyzing the Effect of Disinfection Additives on the Linear Dimensional Stability of Dental Alginate Impressions: A Quasi-Experimental Comparative Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alginates CI brief — competitive landscape report
- Alginates updates RSS · CI watch RSS
- Medical University of South Carolina portfolio CI
Frequently asked questions about Alginates
What is Alginates?
Who makes Alginates?
Is Alginates also known as anything else?
What development phase is Alginates in?
Related
- Manufacturer: Medical University of South Carolina — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Gaviscon Advance
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing